JP2021527125A - Ｓａｒｍ１阻害剤 - Google Patents

Ｓａｒｍ１阻害剤 Download PDF

Info

Publication number
JP2021527125A
JP2021527125A JP2021518045A JP2021518045A JP2021527125A JP 2021527125 A JP2021527125 A JP 2021527125A JP 2021518045 A JP2021518045 A JP 2021518045A JP 2021518045 A JP2021518045 A JP 2021518045A JP 2021527125 A JP2021527125 A JP 2021527125A
Authority
JP
Japan
Prior art keywords
certain embodiments
compound according
disease
sarm1
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527125A5 (https=
Inventor
ロバート・オーエン・ヒューズ
ラジェシュ・デブラジ
トッド・ボサナック
リチャード・アンドリュー・ジャージェス−パイク
アンドリュー・サイモン・ブリアリー
ジョナサン・ベントリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of JP2021527125A publication Critical patent/JP2021527125A/ja
Publication of JP2021527125A5 publication Critical patent/JP2021527125A5/ja
Priority to JP2023203259A priority Critical patent/JP7576145B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021518045A 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤 Pending JP2021527125A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203259A JP7576145B2 (ja) 2018-06-07 2023-11-30 Ｓａｒｍ１阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682033P 2018-06-07 2018-06-07
US62/682,033 2018-06-07
PCT/US2019/035833 WO2019236879A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203259A Division JP7576145B2 (ja) 2018-06-07 2023-11-30 Ｓａｒｍ１阻害剤

Publications (2)

Publication Number Publication Date
JP2021527125A true JP2021527125A (ja) 2021-10-11
JP2021527125A5 JP2021527125A5 (https=) 2022-06-22

Family

ID=68769462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518045A Pending JP2021527125A (ja) 2018-06-07 2019-06-06 Ｓａｒｍ１阻害剤
JP2023203259A Active JP7576145B2 (ja) 2018-06-07 2023-11-30 Ｓａｒｍ１阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203259A Active JP7576145B2 (ja) 2018-06-07 2023-11-30 Ｓａｒｍ１阻害剤

Country Status (8)

Country Link
US (1) US12338238B2 (https=)
EP (1) EP3801500B1 (https=)
JP (2) JP2021527125A (https=)
CN (1) CN112839647B (https=)
CA (1) CA3102645A1 (https=)
ES (1) ES3028093T3 (https=)
MA (1) MA52813A (https=)
WO (1) WO2019236879A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US12595252B2 (en) 2019-06-14 2026-04-07 Disarm Therapeutics, Inc. Inhibitors of SARM1
CA3150878A1 (en) 2019-09-12 2021-03-18 Jonathan Bentley Inhibitors of sarm1
JP7528212B2 (ja) * 2019-11-26 2024-08-05 ディスアーム セラピューティクス， インコーポレイテッド 神経保護のための方法および組成物
US12606558B2 (en) 2020-04-09 2026-04-21 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of SARM1
US12435084B2 (en) 2020-04-09 2025-10-07 Eli Lilly And Company Indazole derivatives as inhibitors of SARM1
IL298577A (en) * 2020-05-27 2023-01-01 Emendobio Inc Biallelic silencing of sarm1
TWI904906B (zh) 2020-08-24 2025-11-11 美商達薩瑪治療公司 Sarm1之抑制劑
WO2023240084A2 (en) * 2022-06-06 2023-12-14 Denali Therapeutics Inc. Compounds, compositions, and methods
EP4539840A4 (en) * 2022-06-17 2026-04-15 Sundance Biosciences Inc Kinase Modulators and Their Methods of Use
WO2024158607A1 (en) 2023-01-24 2024-08-02 Disarm Therapeutics, Inc. Substituted 1h-pyrazole-4-carboxamides as sarm1 inhibitors
TW202509019A (zh) * 2023-04-27 2025-03-01 香港商維泰瑞隆（香港）生物科技有限公司 Sarm1調節子、其製劑及用途

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027969A1 (en) * 1993-05-24 1994-12-08 Zeneca Limited Isoquinolinetrione derivatives as herbicides
JP2004509064A (ja) * 2000-04-27 2004-03-25 アボット・ラボラトリーズ 置換フェニルファルネシルトランスフェラーゼ阻害剤
JP2006515302A (ja) * 2002-12-26 2006-05-25 アルミラル プロデスファルマ ソシエダッド アノニマ 新規ピリダジン−３（２ｈ）−オン誘導体
JP2008543956A (ja) * 2005-06-28 2008-12-04 サノフィ−アベンティス Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体
JP2009502830A (ja) * 2005-07-26 2009-01-29 サノフィ−アベンティス Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
JP2009530336A (ja) * 2006-03-22 2009-08-27 ユセベ ファルマ ソシエテ アノニム １−ハロ−２，７−ナフチリジニル誘導体を調製する方法
JP2009543801A (ja) * 2006-07-13 2009-12-10 ノバルティス アクチエンゲゼルシャフト 神経障害処置におけるトリフルオロメチル置換ベンズアミドの使用
JP2010053073A (ja) * 2008-08-28 2010-03-11 Sankyo Kasei Kk ハロゲン化イソキノリン類の製造方法
JP2011522806A (ja) * 2008-05-30 2011-08-04 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
JP2012517439A (ja) * 2009-02-06 2012-08-02 エラン ファーマシューティカルズ，インコーポレイテッド Ｊｕｎｎ−末端キナーゼの阻害薬
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2014509313A (ja) * 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
WO2015050471A1 (en) * 2013-10-02 2015-04-09 Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" Carbazole compounds and methods of using same
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
JP2015531381A (ja) * 2012-10-02 2015-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍の処置のための７−アザインドール−２，７−ナフチリジン誘導体
WO2016036636A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
JP2017506251A (ja) * 2014-02-21 2017-03-02 レ ラボラトワール セルヴィエ 心血管疾患の処置のための５−ベンジルイソキノリン誘導体
JP2017513919A (ja) * 2014-04-28 2017-06-01 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en) 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
US3429882A (en) 1968-03-25 1969-02-25 Geigy Chem Corp 1,2,8,9-tetraazaphenalenes
US3539567A (en) 1968-04-23 1970-11-10 Geigy Chem Corp 8-carboxy-1(2h) phthalazinones
US3761493A (en) 1968-04-23 1973-09-25 Ciba Geigy Corp 3-dibromomethylphthalic anhydride
US3624108A (en) 1968-04-23 1971-11-30 Geigy Chem Corp 7-carboxyphthalides
US3542777A (en) 1968-08-12 1970-11-24 Geigy Chem Corp Derivatives of 9-pyridylalkyl-1,2,8,9-tetraazaphenalenes
US3517014A (en) 1969-06-16 1970-06-23 Sterling Drug Inc Method of preparing 8-hydroxyquinoline-3-carboxylic acids
US3711473A (en) 1970-04-06 1973-01-16 Ciba Geigy Corp 3-hydrazino-1,2,8,9-tetraazaphenalenes
DE2449252A1 (de) 1973-10-16 1975-04-17 Fuji Photo Film Co Ltd Waermeentwickelbares, lichtempfindliches material
US4207112A (en) 1974-01-29 1980-06-10 Fuji Photo Film Co., Ltd. Heat developable light-sensitive materials
JPS50123331A (https=) 1974-03-14 1975-09-27
US7109208B2 (en) * 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20060078890A1 (en) * 2004-10-08 2006-04-13 Ole Isacson Methods for identifying parkinson's disease therapeutics
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
US20100004244A1 (en) * 2006-06-27 2010-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of cb2 receptor agonists for promoting neurogenesis
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
KR20160023854A (ko) 2013-06-24 2016-03-03 메르크 파텐트 게엠베하 프탈라진 유도체
CA3011189C (en) 2016-01-14 2024-02-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
WO2018035204A1 (en) 2016-08-16 2018-02-22 Henry Ford Health System Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
US11098026B2 (en) * 2017-03-13 2021-08-24 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
CA3108669A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN109223787A (zh) 2018-10-04 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种喜树碱和新型酞嗪酮类化合物联合用药物组合物
CN109336863A (zh) 2018-10-04 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种新型酞嗪酮类btk抑制剂、制备及其应用
CN109485636A (zh) 2018-10-04 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途
CN109180642A (zh) 2018-10-04 2019-01-11 南京先进生物材料与过程装备研究院有限公司 酞嗪酮类btk抑制剂及其应用
CN109293635A (zh) 2018-10-04 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种新型btk激酶抑制剂的p晶型及其制备方法
WO2020081923A1 (en) * 2018-10-19 2020-04-23 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
CN109276571A (zh) 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109481441A (zh) 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
EP4174170A4 (en) 2020-06-25 2023-12-06 FUJIFILM Corporation METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELLS AND USE THEREOF

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027969A1 (en) * 1993-05-24 1994-12-08 Zeneca Limited Isoquinolinetrione derivatives as herbicides
JP2004509064A (ja) * 2000-04-27 2004-03-25 アボット・ラボラトリーズ 置換フェニルファルネシルトランスフェラーゼ阻害剤
JP2006515302A (ja) * 2002-12-26 2006-05-25 アルミラル プロデスファルマ ソシエダッド アノニマ 新規ピリダジン−３（２ｈ）−オン誘導体
JP2008543956A (ja) * 2005-06-28 2008-12-04 サノフィ−アベンティス Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体
JP2009502830A (ja) * 2005-07-26 2009-01-29 サノフィ−アベンティス Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
JP2009530336A (ja) * 2006-03-22 2009-08-27 ユセベ ファルマ ソシエテ アノニム １−ハロ−２，７−ナフチリジニル誘導体を調製する方法
JP2009543801A (ja) * 2006-07-13 2009-12-10 ノバルティス アクチエンゲゼルシャフト 神経障害処置におけるトリフルオロメチル置換ベンズアミドの使用
JP2011522806A (ja) * 2008-05-30 2011-08-04 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
JP2010053073A (ja) * 2008-08-28 2010-03-11 Sankyo Kasei Kk ハロゲン化イソキノリン類の製造方法
JP2012517439A (ja) * 2009-02-06 2012-08-02 エラン ファーマシューティカルズ，インコーポレイテッド Ｊｕｎｎ−末端キナーゼの阻害薬
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
JP2014509313A (ja) * 2011-02-01 2014-04-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ７−アザインドール誘導体
JP2015531381A (ja) * 2012-10-02 2015-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍の処置のための７−アザインドール−２，７−ナフチリジン誘導体
WO2015050471A1 (en) * 2013-10-02 2015-04-09 Obschestvo S Ogranichennoy Otvetstvennost'yu "Panacela Labs" Carbazole compounds and methods of using same
WO2015102929A1 (en) * 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
JP2017506251A (ja) * 2014-02-21 2017-03-02 レ ラボラトワール セルヴィエ 心血管疾患の処置のための５−ベンジルイソキノリン誘導体
JP2017513919A (ja) * 2014-04-28 2017-06-01 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
WO2016036636A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY[ONLINE], JPN7023001996, ISSN: 0005259732 *

Also Published As

Publication number Publication date
ES3028093T3 (en) 2025-06-18
MA52813A (fr) 2021-04-14
EP3801500A4 (en) 2022-03-02
CN112839647B (zh) 2025-09-23
CN112839647A (zh) 2021-05-25
US12338238B2 (en) 2025-06-24
EP3801500B1 (en) 2025-03-05
EP3801500A1 (en) 2021-04-14
JP2024037770A (ja) 2024-03-19
US20210261540A1 (en) 2021-08-26
WO2019236879A1 (en) 2019-12-12
JP7576145B2 (ja) 2024-10-30
CA3102645A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7576145B2 (ja) Ｓａｒｍ１阻害剤
JP2021528488A (ja) Ｓａｒｍ１阻害剤
JP7289375B2 (ja) Ｓａｒｍ１の阻害剤
JP2021527126A (ja) Ｓａｒｍ１阻害剤
JP7212781B2 (ja) 神経保護剤と組み合わせたｓａｒｍ１の阻害剤
JP7478252B2 (ja) Ｓａｒｍ１の阻害剤
TW202140437A (zh) Sarm1抑制劑
JP7534390B2 (ja) Ｓａｒｍ１の阻害剤
JP7477642B2 (ja) Ｓａｒｍ１の阻害剤
US20240051939A1 (en) Benzopyrazole inhibitors of sarm1
CA3102598C (en) Inhibitors of sarm1

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210409

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240213